Sandell Rolf, Svensson Martin, Nilsson Thomas, Johansson Håkan, Viborg Gardar, Perrin Sean
Department of Psychology, Lund University, Box 213, Lund, 221 00, Sweden.
Institute of Psychiatry, Psychology and Neurosciences, Box PO77, King's College London, 16 DeCrespigny Park, London, SE5 8AF, UK.
Trials. 2015 Mar 31;16:130. doi: 10.1186/s13063-015-0656-7.
Panic disorder with or without agoraphobia is a commonly occurring disorder affecting 2 to 3% of the population in Sweden. Untreated, panic disorder is a chronic condition that significantly increases the risk for psychiatric comorbidity, morbidity and mortality, employment difficulties, and healthcare utilization. Cognitive behavioral approaches are the recommended first-line treatment for panic disorder; however, many patients in routine care receive another evidence-based psychotherapy, including psychodynamic therapy. Allowing patients to choose among evidence-based approaches to panic disorder may improve outcomes and reduce overall health costs. Trials comparing the 'gold standard' treatment for panic disorder to other evidence-based psychotherapies are needed, and also trials that can separate patient preferences for treatment from randomization effects on outcome, disability and healthcare utilization in the longer term.
METHODS/DESIGN: A phase 2/3 doubly-randomized controlled trial carried out in routine care with 216 adults (aged 18 to 70 years) with a primary diagnosis of DSM-IV Panic Disorder (with or without Agoraphobia). Within each clinic, patients are randomized to self-selection, random assignment of treatment, or wait-list. Patients choose or are randomly assigned to either Panic Control Treatment or Panic-Focused Psychodynamic Psychotherapy. Primary outcomes are changes in panic symptom severity, occupational status, and sickness-related absences from work at post-treatment and 6, 12 and 24 months post-treatment. Secondary outcomes include changes in agoraphobic avoidance, psychiatric comorbidity, disability, and healthcare utilization. The study also employs elements of an effectiveness trial as therapist and service-related effects on outcome will be estimated. Putative change mechanisms for the two treatments are also assessed.
Cognitive behavioral and psychodynamic therapies are both evidence-based approaches that are routinely offered to panic disordered patients in Sweden. However, little is known about the relative effectiveness of these two approaches for panic/agoraphobia, work-related disability and healthcare utilization over the longer term. The current trial (POSE) also addresses the important but understudied issue of whether patient preference for a particular psychotherapeutic approach moderates outcome.
ClinicalTrials.gov NCT01606592 (registered 19 March 2012).
伴有或不伴有广场恐惧症的惊恐障碍是一种常见疾病,在瑞典影响着2%至3%的人口。未经治疗的惊恐障碍是一种慢性疾病,会显著增加精神共病、发病率和死亡率、就业困难以及医疗保健利用率的风险。认知行为疗法是惊恐障碍推荐的一线治疗方法;然而,许多接受常规治疗的患者会接受另一种循证心理治疗,包括精神动力疗法。允许患者在惊恐障碍的循证治疗方法中进行选择可能会改善治疗效果并降低总体医疗成本。需要进行试验,将惊恐障碍的“金标准”治疗与其他循证心理治疗方法进行比较,还需要进行试验,以便从长期来看,能够将患者对治疗的偏好与随机化对治疗效果、残疾和医疗保健利用率的影响区分开来。
方法/设计:在常规护理中开展一项2/3期双随机对照试验,纳入216名年龄在18至70岁之间、初步诊断为DSM-IV惊恐障碍(伴有或不伴有广场恐惧症)的成年人。在每个诊所内,患者被随机分为自我选择组、随机分配治疗组或等待名单组。患者选择或被随机分配接受惊恐控制治疗或惊恐聚焦精神动力心理治疗。主要结局指标为治疗后以及治疗后6个月、12个月和24个月时惊恐症状严重程度、职业状况以及与疾病相关的缺勤情况的变化。次要结局指标包括广场恐惧回避、精神共病、残疾和医疗保健利用率的变化。该研究还采用了有效性试验的要素,因为将评估治疗师和服务相关因素对治疗效果的影响。还将评估两种治疗方法的假定改变机制。
认知行为疗法和精神动力疗法都是循证治疗方法,在瑞典通常提供给患有惊恐障碍的患者。然而,对于这两种方法在惊恐/广场恐惧症、与工作相关的残疾和医疗保健利用率方面的长期相对有效性,人们了解甚少。当前的试验(POSE)还解决了一个重要但研究不足的问题,即患者对特定心理治疗方法的偏好是否会影响治疗效果。
ClinicalTrials.gov NCT01606592(2012年3月19日注册)。